Dopaminergic Enhancement of Learning and Memory in Aphasia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00102869 |
Recruitment Status
:
Completed
First Posted
: February 4, 2005
Last Update Posted
: October 7, 2013
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cerebrovascular Accident Aphasia | Drug: levodopa | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 12 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Aphasia) |
Study Start Date : | January 2005 |
Actual Primary Completion Date : | February 2007 |
Actual Study Completion Date : | December 2008 |

-
Drug: levodopa
- Boost in naming performance (percent correct) through levodopa as compared to placebo [ Time Frame: immediately after each treatmentphase ]
- Brain activity pattern in successfully trained patients [ Time Frame: immediately after each treatmentphase ]
- Stability of naming performance after one month and six months post treatment [ Time Frame: from 1 month untill 6 months after treatment completion ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria for patients with aphasia:
- Unilateral cerebrovascular accident (stroke) in the territory of the arteria media
- Time post onset: > 6 months
- Aphasia with anomia
- Age between 18-75 years
- Premorbid right-handedness
- Primary language: German
Exclusion Criteria for patients and healthy controls:
- Known allergy to levodopa or tartrazine
- History of medication/drug abuse
- Acute nicotine withdrawal or > 15 cigarettes per day
- > 6 cups/glasses of coffee, caffeine drinks or energy drinks per day
- > 50 grams of alcohol per day
- Severe hypertonia (systole >180 mm Hg)
- Severe arteriosclerosis
- Diabetes, asthma, or glaucoma
- Severe hearing disability
- Evidence for severe hippocampal damage
- Premorbid depression or psychosis
- Medication with dopamine agonists or antagonists
- Parkinsonian symptoms
- Changes in anticonvulsive medication during the week prior to study enrollment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00102869
Germany | |
Dept. of Neurology, University Hospital Muenster | |
Muenster, Nordrhein-Westfalen, Germany, 48129 |
Study Director: | Caterina Breitenstein, PhD | Dept. of Neurology, University Hospital Muenster, Germany | |
Study Chair: | Stefan Knecht, MD | Dept. of Neurology, University Hospital Muenster, Germany |
Additional Information:
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Rainer Girgenrath, Bundesministerium für Bildung und Forschung (BMBF) |
ClinicalTrials.gov Identifier: | NCT00102869 History of Changes |
Other Study ID Numbers: |
LL_001, Project on aphasia |
First Posted: | February 4, 2005 Key Record Dates |
Last Update Posted: | October 7, 2013 |
Last Verified: | June 2008 |
Keywords provided by University Hospital Muenster:
language acquisition plasticity stroke recovery aphasia treatment |
naming levodopa stroke |
Additional relevant MeSH terms:
Aphasia Stroke Speech Disorders Language Disorders Communication Disorders Neurobehavioral Manifestations Neurologic Manifestations Nervous System Diseases Signs and Symptoms Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Vascular Diseases Cardiovascular Diseases |
Levodopa Dopamine Dopamine Agents Dopamine Agonists Antiparkinson Agents Anti-Dyskinesia Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Cardiotonic Agents Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Protective Agents |